Skip to main content
. 2012 Apr 19;4:113–119. doi: 10.2147/CMAR.S30431

Figure 1.

Figure 1

Comparison of the local control rates between the miriplatin (solid line) and epirubicin (dotted line) groups in the targeted chemoembolization of hepatocellular carcinoma.

Note: The miriplatin group showed significantly higher local tumor progression as compared to the epirubicin group (P < 0.001).